Samsung Invests in Generate to Advance AI-driven Protein Therapeutics Discovery

This KRW 240 billion fund, managed by Samsung Venture Investment Corporation, has been used to support biotech companies with promising technologies, with a focus on driving innovation in the life sciences sector.

Samsung has made a strategic investment in Generate, a move aimed at fostering growth and innovation within the biopharmaceutical industry. The investment is part of Samsung's ongoing commitment to advancing AI-enabled therapeutic development.

The funding was made through the Samsung Life Science Fund, established in 2021. This KRW 240 billion fund, managed by Samsung Venture Investment Corporation, has been used to support biotech companies with promising technologies, with a focus on driving innovation in the life sciences sector.

Generate, a clinical-stage company founded by Flagship Pioneering, specializes in generative biology. The company applies artificial intelligence (AI) to optimize and generate novel protein therapeutics, addressing critical areas such as oncology, immunology, and infectious diseases. Generate's pipeline includes approximately 20 programs currently in various stages of preclinical and clinical development.

“We see great potential in Generate to develop first- and best-in-class therapeutics. Leveraging Generate’s strengths in AI and machine learning, we look forward to creating an ecosystem for development, manufacturing, and R&D collaboration to advance next-generation medicines in areas with unmet needs,” said John Rim, President and CEO of Samsung Biologics.

Mike Nally, CEO of Generate: Biomedicines, expressed optimism about the future of the partnership, stating, “Funding from leading partners like Samsung enables us to continue advancing our platform, generating high-quality data, and empowering our exceptional team to tackle some of the toughest challenges in human health. With clinical programs already in progress and plans to add three to six more within the next 18 months, we are turning technological promise into tangible outcomes.”

Samsung Biologics, which provides comprehensive contract development and manufacturing services (CDMO), is actively expanding its capabilities to meet the growing demand for biomanufacturing. The company is committed to delivering high-quality, on-time services, supporting the development of next-generation therapeutics.

Stay tuned for more such updates on Digital Health News.